Showing 2471-2480 of 4902 results for "".
The State of Dermatology Entrepreneurship 2015
https://practicaldermatology.com/topics/practice-management/the-state-of-dermatology-entrepreneurship-2015/18913/William Ju, MD, President of Advancing Innovation in Dermatology talks about entrepreneurship in dermatology. Where are new ideas, technologies, and therapies coming from, and how will they move ahead? Dr. Ju talks about the role of the pharmaceutical industry and finding resources.The Importance of Skincare
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-importance-of-skincare/19035/Whether patients want lasers, injectables, Botox, or cosmeceuticals, they need guidance on proper skincare to prevent wrinkles and skin cancer, says Dina Anderson, MD, FAAD. Patients need to learn about antioxidants, free radicals, and the effects of smoking.Heliocare in Practice
https://practicaldermatology.com/topics/practice-management/heliocare-in-practice/19220/Polypodium leucotomos extract, which is derived from a tropical fern, offers benefits to users by minimizing some of the damage to the skin caused by exposure to visible light—UVA and UVB radiation—as well as invisible infrared light. Vivian Bucay, MD, discusses its activity and its role as a dispenDermWire TV Extra: Dr. Ruiz on GEP Testing for SCC
https://practicaldermatology.com/topics/skin-of-color/dermwire-tv-extra-dr-ruiz-gep-testing-scc/29497/Emily Ruiz, MD, MPH, FAAD, a Mohs surgeon at Brigham and Women's Hospital and cutaneous oncologist at Dana-Farber Cancer Institute, discusses her recent Future Oncology article, "Predicting adjuvant radiation therapy benefit in cutaneous squamous cell carcinoma with the 40-gene expression profile."Skin of Color Session: Dr. Harris
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/skin-of-color-session-dr-harris/32683/John E. Harris, MD, PhD, summarizes his vitiligo talk from the "Skin of Color Session" at Maui Derm 2025, during which he covered new therapeutic options for vitiligo as well as promising drugs in the pipeline and why they could be so impactful.New Drug Developments in Dermatology
https://practicaldermatology.com/topics/skin-cancer-photoprotection/new-drug-developments-in-dermatology/19971/Despite the COVID pandemic, the FDA had a nearly record year in drug approvals, says Vinod Nambudiri, MD, MBA, which has translated to new developments in dermatology. He discusses approvals of tirbanibulin 1% ointment for actinic keratoses and clascoterone cream 1% for acne, and how they fit into tCOVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.An Updated, Holistic Approach to Managing Hyperpigmentation
https://practicaldermatology.com/topics/pigmentary-disorders/an-updated-holistic-approach-to-managing-hyperpigmentation/20102/As an early adopter of Cyspera, Suneel Chilukuri, MD has witnessed the evolution of the topical formulation. Cyspera Intensive System provides a three-step holistic approach to skincare that supports healthier, brighter skin within about four to six weeks.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.